{"title":"RE: Comment on: \"Implementing a no-drain policy for extraperitoneal colorectal anastomosis in a real-life setting: analysis of outcomes and surgeons' adherence\".","authors":"Jacopo Crippa, Michele Carvello, Antonino Spinelli","doi":"10.1007/s00384-024-04749-x","DOIUrl":"10.1007/s00384-024-04749-x","url":null,"abstract":"","PeriodicalId":13789,"journal":{"name":"International Journal of Colorectal Disease","volume":"39 1","pages":"177"},"PeriodicalIF":2.5,"publicationDate":"2024-10-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11527930/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142557792","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-10-31DOI: 10.1007/s00384-024-04754-0
Dhivya Viswanathan, Rajakumar Govindasamy
{"title":"Commentary: treatment indicators and prognostic factors in colorectal neuroendocrine neoplasms and adenocarcinoma with neuroendocrine differentiation.","authors":"Dhivya Viswanathan, Rajakumar Govindasamy","doi":"10.1007/s00384-024-04754-0","DOIUrl":"10.1007/s00384-024-04754-0","url":null,"abstract":"","PeriodicalId":13789,"journal":{"name":"International Journal of Colorectal Disease","volume":"39 1","pages":"176"},"PeriodicalIF":2.5,"publicationDate":"2024-10-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11527906/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142557771","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-10-31DOI: 10.1007/s00384-024-04743-3
Zhen Li, Zhong Chen, Chun Liu, Shuang Peng, Ning Wang
Background: Hemorrhoids are very common in patients with human immunodeficiency virus (HIV) infection. The risk of postoperative infection is significantly greater in HIV-positive patients than in HIV-negative individuals, and the wound healing time is significantly prolonged. This study aimed to investigate the role of HIV-associated hemorrhoids from the perspective of vascular smooth muscle cell (VSMC) function.
Methods: A total of 24 hemorrhoid tissue samples (note: grade IV hemorrhoids were absence) were collected and subjected to Masson staining to evaluate fibrosis in this study. mRNA and protein levels were monitored by qPCR and WB analysis, respectively. Immunofluorescence was conducted to evaluate PKG1 and α-SMA expression. To establish a cell model in vitro, VSMCs were stimulated with envelope glycoprotein (gp) 120, which is a type of HIV envelope protein. Cell proliferation was assessed via a CCK-8 assay and EdU staining. Moreover, a wound healing assay was performed to assess cell migration.
Results: Our data confirmed that fibrosis was present in hemorrhoid tissues from HIV-infected patients and that PKG1 expression was upregulated. Moreover, the administration of HIV gp120 promoted the proliferation and migration of VSMCs. Similarly, fibrosis-related markers (α-SMA, MMP2, MMP3, and TIMP1) were markedly upregulated. However, silencing PKG1 inhibited the proliferation, migration, and expression of fibrosis-related markers in gp120-challenged VSMCs.
Conclusion: The present research revealed that PKG1 regulated the proliferation, migration, and fibrosis of VSMCs, thereby exerting detrimental effects on HIV-associated hemorrhoids.
背景:痔疮在人类免疫缺陷病毒(HIV)感染患者中非常常见。HIV 阳性患者术后感染的风险明显高于 HIV 阴性患者,伤口愈合时间也明显延长。本研究旨在从血管平滑肌细胞(VSMC)功能的角度研究艾滋病毒相关性痔疮的作用:本研究共收集了 24 份痔疮组织样本(注:不包括 IV 级痔疮),并采用 Masson 染色法评估纤维化情况。免疫荧光法评估 PKG1 和 α-SMA 的表达。为了在体外建立细胞模型,用包膜糖蛋白(gp)120(一种 HIV 包膜蛋白)刺激 VSMC。细胞增殖通过 CCK-8 试验和 EdU 染色进行评估。此外,还进行了伤口愈合试验以评估细胞迁移:结果:我们的数据证实,HIV 感染者的痔疮组织存在纤维化,PKG1 表达上调。此外,HIV gp120 能促进 VSMC 的增殖和迁移。同样,纤维化相关标记物(α-SMA、MMP2、MMP3 和 TIMP1)也明显上调。然而,沉默PKG1可抑制gp120挑战的VSMCs的增殖、迁移和纤维化相关标志物的表达:本研究揭示了PKG1调控VSMCs的增殖、迁移和纤维化,从而对HIV相关性痔疮产生不利影响。
{"title":"PKG1 promotes the HIV-induced proliferation, migration, and fibrosis of vascular smooth muscle cells of hemorrhoids.","authors":"Zhen Li, Zhong Chen, Chun Liu, Shuang Peng, Ning Wang","doi":"10.1007/s00384-024-04743-3","DOIUrl":"10.1007/s00384-024-04743-3","url":null,"abstract":"<p><strong>Background: </strong>Hemorrhoids are very common in patients with human immunodeficiency virus (HIV) infection. The risk of postoperative infection is significantly greater in HIV-positive patients than in HIV-negative individuals, and the wound healing time is significantly prolonged. This study aimed to investigate the role of HIV-associated hemorrhoids from the perspective of vascular smooth muscle cell (VSMC) function.</p><p><strong>Methods: </strong>A total of 24 hemorrhoid tissue samples (note: grade IV hemorrhoids were absence) were collected and subjected to Masson staining to evaluate fibrosis in this study. mRNA and protein levels were monitored by qPCR and WB analysis, respectively. Immunofluorescence was conducted to evaluate PKG1 and α-SMA expression. To establish a cell model in vitro, VSMCs were stimulated with envelope glycoprotein (gp) 120, which is a type of HIV envelope protein. Cell proliferation was assessed via a CCK-8 assay and EdU staining. Moreover, a wound healing assay was performed to assess cell migration.</p><p><strong>Results: </strong>Our data confirmed that fibrosis was present in hemorrhoid tissues from HIV-infected patients and that PKG1 expression was upregulated. Moreover, the administration of HIV gp120 promoted the proliferation and migration of VSMCs. Similarly, fibrosis-related markers (α-SMA, MMP2, MMP3, and TIMP1) were markedly upregulated. However, silencing PKG1 inhibited the proliferation, migration, and expression of fibrosis-related markers in gp120-challenged VSMCs.</p><p><strong>Conclusion: </strong>The present research revealed that PKG1 regulated the proliferation, migration, and fibrosis of VSMCs, thereby exerting detrimental effects on HIV-associated hemorrhoids.</p>","PeriodicalId":13789,"journal":{"name":"International Journal of Colorectal Disease","volume":"39 1","pages":"175"},"PeriodicalIF":2.5,"publicationDate":"2024-10-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11525407/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142545293","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-10-28DOI: 10.1007/s00384-024-04746-0
Stefano Agnesi, Francesco Virgilio, Alice Frontali, Greta Zoni, Mariagiulia Giugliano, Claudio Missaglia, Andrea Balla, Pierpaolo Sileri, Andrea Vignali
Purpose: The aim of this study is to analyze the impact of different surgical techniques used to preserve the inferior mesenteric artery on patient outcomes following left colonic resection.
Methods: A search was conducted in PubMed, Embase and Web of Science, founding 4795 articles. The review was registered on PROSPERO (registration number: CRD42024572291).
Results: Eleven articles published between 2001 and 2023, including 989 patients were the object of the present systematic review. Two hundred sixty-two patients (26.5%) underwent Valdoni's technique (Group A), which involves the skeletonization of the IMA, 272 (27.5%) underwent tubular resection (Group B), and 455 (46%) underwent peripheral dissection on sigmoid vessels (Group C). Laparoscopic surgery was predominant in Groups B (100%) and C (94.7%), while Group A had fewer laparoscopic procedures (44.6%). Patients in Group A experienced longer operative times (174.5 ± 27.4 min) and hospital stays (11.4 ± 3.6 days) compared to Groups B and C (165.9 min and 152.35 ± 46.9 min; 8.4 ± 5.7 days and 8.3 ± 3.6 days, respectively). Group A exhibited higher rates of anastomotic leakage (5%) compared to Group C (1.1%) and a higher incidence of bleeding (13%) compared to Group B (1.8%).
Conclusion: Valdoni's technique is less favourable for IMA preservation in left colon resection for diverticular disease. Peripheral dissection of sigmoid vessels or tubular resection is recommended for IMA preservation in this context.
目的:本研究旨在分析保留肠系膜下动脉的不同手术技术对左结肠切除术后患者预后的影响:在 PubMed、Embase 和 Web of Science 中进行了检索,共发现 4795 篇文章。该综述已在 PROSPERO 上注册(注册号:CRD42024572291):本系统综述的对象是2001年至2023年间发表的11篇文章,包括989名患者。262 名患者(26.5%)接受了瓦尔多尼技术(A 组),包括 IMA 骨架化;272 名患者(27.5%)接受了管状切除术(B 组);455 名患者(46%)接受了乙状结肠血管外围解剖(C 组)。B 组(100%)和 C 组(94.7%)主要采用腹腔镜手术,而 A 组采用腹腔镜手术的人数较少(44.6%)。与 B 组和 C 组(分别为 165.9 分钟和 152.35 ± 46.9 分钟;8.4 ± 5.7 天和 8.3 ± 3.6 天)相比,A 组患者的手术时间(174.5 ± 27.4 分钟)和住院时间(11.4 ± 3.6 天)更长。A组吻合口漏发生率(5%)高于C组(1.1%),出血发生率(13%)高于B组(1.8%):结论:在左侧结肠憩室疾病切除术中,Valdoni 技术对保留 IMA 的效果较差。在这种情况下,建议采用乙状结肠血管周边剥离术或管状切除术来保留 IMA。
{"title":"Inferior mesenteric artery preservation techniques in the treatment of diverticular disease: a systematic review of the literature.","authors":"Stefano Agnesi, Francesco Virgilio, Alice Frontali, Greta Zoni, Mariagiulia Giugliano, Claudio Missaglia, Andrea Balla, Pierpaolo Sileri, Andrea Vignali","doi":"10.1007/s00384-024-04746-0","DOIUrl":"10.1007/s00384-024-04746-0","url":null,"abstract":"<p><strong>Purpose: </strong>The aim of this study is to analyze the impact of different surgical techniques used to preserve the inferior mesenteric artery on patient outcomes following left colonic resection.</p><p><strong>Methods: </strong>A search was conducted in PubMed, Embase and Web of Science, founding 4795 articles. The review was registered on PROSPERO (registration number: CRD42024572291).</p><p><strong>Results: </strong>Eleven articles published between 2001 and 2023, including 989 patients were the object of the present systematic review. Two hundred sixty-two patients (26.5%) underwent Valdoni's technique (Group A), which involves the skeletonization of the IMA, 272 (27.5%) underwent tubular resection (Group B), and 455 (46%) underwent peripheral dissection on sigmoid vessels (Group C). Laparoscopic surgery was predominant in Groups B (100%) and C (94.7%), while Group A had fewer laparoscopic procedures (44.6%). Patients in Group A experienced longer operative times (174.5 ± 27.4 min) and hospital stays (11.4 ± 3.6 days) compared to Groups B and C (165.9 min and 152.35 ± 46.9 min; 8.4 ± 5.7 days and 8.3 ± 3.6 days, respectively). Group A exhibited higher rates of anastomotic leakage (5%) compared to Group C (1.1%) and a higher incidence of bleeding (13%) compared to Group B (1.8%).</p><p><strong>Conclusion: </strong>Valdoni's technique is less favourable for IMA preservation in left colon resection for diverticular disease. Peripheral dissection of sigmoid vessels or tubular resection is recommended for IMA preservation in this context.</p>","PeriodicalId":13789,"journal":{"name":"International Journal of Colorectal Disease","volume":"39 1","pages":"174"},"PeriodicalIF":2.5,"publicationDate":"2024-10-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11519083/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142521818","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-10-28DOI: 10.1007/s00384-024-04751-3
Leena-Mari Mäntymäki, Juha Grönroos, Jukka Karvonen, Mika Ukkonen
{"title":"Correction to: A novel scoring system for predicting disease severity without CT imaging in acute diverticulitis.","authors":"Leena-Mari Mäntymäki, Juha Grönroos, Jukka Karvonen, Mika Ukkonen","doi":"10.1007/s00384-024-04751-3","DOIUrl":"10.1007/s00384-024-04751-3","url":null,"abstract":"","PeriodicalId":13789,"journal":{"name":"International Journal of Colorectal Disease","volume":"39 1","pages":"172"},"PeriodicalIF":2.5,"publicationDate":"2024-10-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11513734/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142499851","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-10-28DOI: 10.1007/s00384-024-04748-y
Vahid Khaze Shahgoli, Saeed Noorolyai, Mahya Ahmadpour Youshanlui, Hossein Saeidi, Hadi Nasiri, Behzad Mansoori, Uffe Holmskov, Behzad Baradaran
Background: Chronic inflammation is a significant driver in the development of various diseases, including cancer. Colitis-associated colorectal cancer (CA-CRC) refers to the increased risk of colorectal cancer in individuals with chronic inflammatory bowel diseases (IBD) such as ulcerative colitis and Crohn's disease.
Methods: This narrative review examines the link between chronic inflammation and CA-CRC. A comprehensive literature search was conducted using PubMed, Scopus, and Web of Science, focusing on studies published between 2000 and 2024. Studies were selected based on relevance to the role of inflammation in CA-CRC, specifically targeting molecular pathways and clinical implications. Both clinical and mechanistic studies were reviewed.
Conclusion: Sustained inflammation in the colon fosters a pro-tumorigenic environment, leading to the initiation and progression of CA-CRC. Prevention strategies must focus on controlling chronic inflammation, optimizing IBD management, and implementing regular screenings. Emerging therapies targeting key inflammatory pathways and immune responses, along with microbiome modulation, hold promise for reducing CA-CRC risk. Understanding these molecular mechanisms provides a path toward personalized treatment and better outcomes for patients with IBD at risk of colorectal cancer.
{"title":"Inflammatory bowel disease, colitis, and cancer: unmasking the chronic inflammation link.","authors":"Vahid Khaze Shahgoli, Saeed Noorolyai, Mahya Ahmadpour Youshanlui, Hossein Saeidi, Hadi Nasiri, Behzad Mansoori, Uffe Holmskov, Behzad Baradaran","doi":"10.1007/s00384-024-04748-y","DOIUrl":"10.1007/s00384-024-04748-y","url":null,"abstract":"<p><strong>Background: </strong>Chronic inflammation is a significant driver in the development of various diseases, including cancer. Colitis-associated colorectal cancer (CA-CRC) refers to the increased risk of colorectal cancer in individuals with chronic inflammatory bowel diseases (IBD) such as ulcerative colitis and Crohn's disease.</p><p><strong>Methods: </strong>This narrative review examines the link between chronic inflammation and CA-CRC. A comprehensive literature search was conducted using PubMed, Scopus, and Web of Science, focusing on studies published between 2000 and 2024. Studies were selected based on relevance to the role of inflammation in CA-CRC, specifically targeting molecular pathways and clinical implications. Both clinical and mechanistic studies were reviewed.</p><p><strong>Conclusion: </strong>Sustained inflammation in the colon fosters a pro-tumorigenic environment, leading to the initiation and progression of CA-CRC. Prevention strategies must focus on controlling chronic inflammation, optimizing IBD management, and implementing regular screenings. Emerging therapies targeting key inflammatory pathways and immune responses, along with microbiome modulation, hold promise for reducing CA-CRC risk. Understanding these molecular mechanisms provides a path toward personalized treatment and better outcomes for patients with IBD at risk of colorectal cancer.</p>","PeriodicalId":13789,"journal":{"name":"International Journal of Colorectal Disease","volume":"39 1","pages":"173"},"PeriodicalIF":2.5,"publicationDate":"2024-10-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11513726/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142499853","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Background: Metastatic colorectal cancer (mCRC) poses a clinical challenge and requires a combination of systemic therapy and conversion surgery. Although first-line chemotherapy and targeted therapy are considered the standard treatments for mCRC, the role of primary tumor resection (PTR) in asymptomatic synchronous mCRC with unresectable metastatic lesion after initial therapy remains relatively underexplored.
Materials: A retrospective review was conducted from January 2015 to January 2021, involving 74 patients with synchronous mCRC who received bevacizumab plus FOFIRI as first-line systemic therapy. All 74 patients had unresectable metastatic lesions confirmed through multidisciplinary team discussion. Patient characteristics, PTR data, and radiotherapy (RT) and overall survival (OS) outcomes were analyzed. The patients were categorized into a "PTR" group and a "No PTR" group and then further stratified into "4A," "4B," and "4C" subgroups based on the initial mCRC stage. Additionally, four subgroups-namely "PTR( +)/RT( +)," "PTR( +)/RT( -)," "PTR( -)/RT( +)," and "PTR( -)/RT( -)"-were formed to assess the combined effects of PTR and RT.
Results: The median OS for all the patients was 23.8 months (20.5-27.1 months). The "PTR" group exhibited a significantly higher median OS of 25.9 months (21.3-30.5 months) compared with 21.4 months (15.8-27.1 months) in the "No PTR" group (p = 0.048). Subgroup analyses revealed a trend of improved survival with PTR in patients with stage IVA and IVB; however, the results were not statistically significant (p = 0.116 and 0.493, respectively). A subgroup analysis of PTR and RT combinations revealed no significant difference in median OS rates.
Conclusion: For asymptomatic mCRC with synchronous unresectable distant metastasis, PTR following first-line therapy with bevacizumab plus FOLFIRI may provide a potential survival benefit, particularly in stage IVA/IVB patients compared with stage IVC patients. Additionally, RT for primary tumor did not provide an additional OS benefit in mCRC with unresectable metastasis. A prospective randomized trial with a larger sample size is essential to further elucidate the role of PTR in this context.
{"title":"Impact on survival benefits of asymptomatic primary tumor resection after bevacizumab plus FOLFIRI as first-line therapy for patients with metastatic colorectal cancer with synchronous unresectable metastasis.","authors":"Yen-Cheng Chen, Tsung-Kun Chang, Wei-Chih Su, Yung-Sung Yeh, Po-Jung Chen, Peng-Jen Huang, Po-Hsiang Yang, Hsiang-Lin Tsai, Jaw-Yuan Wang, Ching-Wen Huang","doi":"10.1007/s00384-024-04745-1","DOIUrl":"10.1007/s00384-024-04745-1","url":null,"abstract":"<p><strong>Background: </strong>Metastatic colorectal cancer (mCRC) poses a clinical challenge and requires a combination of systemic therapy and conversion surgery. Although first-line chemotherapy and targeted therapy are considered the standard treatments for mCRC, the role of primary tumor resection (PTR) in asymptomatic synchronous mCRC with unresectable metastatic lesion after initial therapy remains relatively underexplored.</p><p><strong>Materials: </strong>A retrospective review was conducted from January 2015 to January 2021, involving 74 patients with synchronous mCRC who received bevacizumab plus FOFIRI as first-line systemic therapy. All 74 patients had unresectable metastatic lesions confirmed through multidisciplinary team discussion. Patient characteristics, PTR data, and radiotherapy (RT) and overall survival (OS) outcomes were analyzed. The patients were categorized into a \"PTR\" group and a \"No PTR\" group and then further stratified into \"4A,\" \"4B,\" and \"4C\" subgroups based on the initial mCRC stage. Additionally, four subgroups-namely \"PTR( +)/RT( +),\" \"PTR( +)/RT( -),\" \"PTR( -)/RT( +),\" and \"PTR( -)/RT( -)\"-were formed to assess the combined effects of PTR and RT.</p><p><strong>Results: </strong>The median OS for all the patients was 23.8 months (20.5-27.1 months). The \"PTR\" group exhibited a significantly higher median OS of 25.9 months (21.3-30.5 months) compared with 21.4 months (15.8-27.1 months) in the \"No PTR\" group (p = 0.048). Subgroup analyses revealed a trend of improved survival with PTR in patients with stage IVA and IVB; however, the results were not statistically significant (p = 0.116 and 0.493, respectively). A subgroup analysis of PTR and RT combinations revealed no significant difference in median OS rates.</p><p><strong>Conclusion: </strong>For asymptomatic mCRC with synchronous unresectable distant metastasis, PTR following first-line therapy with bevacizumab plus FOLFIRI may provide a potential survival benefit, particularly in stage IVA/IVB patients compared with stage IVC patients. Additionally, RT for primary tumor did not provide an additional OS benefit in mCRC with unresectable metastasis. A prospective randomized trial with a larger sample size is essential to further elucidate the role of PTR in this context.</p>","PeriodicalId":13789,"journal":{"name":"International Journal of Colorectal Disease","volume":"39 1","pages":"171"},"PeriodicalIF":2.5,"publicationDate":"2024-10-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11511701/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142499852","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-10-22DOI: 10.1007/s00384-024-04731-7
Xiaoying Fu, Cun Wang, Yongyang Yu, Hai-Ning Chen
Purpose: This study compared survival and metastasis occurrence between colorectal neuroendocrine neoplasms (cNEN) and colorectal adenocarcinoma with neuroendocrine differentiation (cNED) and further explored their prognostic factors and treatment indicators.
Methods: Patients diagnosed as cNEN and cNED in West China Hospital from January 2009 to December 2020 were enrolled. The diagnosis and metastasis rates were calculated. Univariate and multivariate Cox analyses were conducted for progression-free survival (PFS) in cNEN surgical patients, and generalized linear regression was used for metastatic disease.
Result: The study enrolled 435 patients, including 257 neuroendocrine tumors (NET), 52 neuroendocrine carcinomas (NEC), 29 mixed neuroendocrine-non-neuroendocrine neoplasms (MiNEN), and 97 NED patients, of whom 202 received local resection, and 233 received radical resection. Metastasis rates were higher in MiNEN and NEC groups compared to other groups (NED: 28.9%, MiNEN: 58.6%, NEC: 65.4%, NET: 8.6%, p < 0.001). The liver is the main metastatic site in cNEN, whereas cNED metastasized to various sites. For NEC and MiNEN patients, colon location (p = 0.002) and T stage > 2 (p = 0.040) were associated with disease progression separately. Independent risk factors for metastatic NET included tumor grade G2/G3 (p < 0.001), colon location (p = 0.001), size ≥ 1 cm (p = 0.005), and CK20 partial positive (p < 0.001).
Conclusion: cNEN show high metastatic capacity and are challenging to diagnose. More aggressive treatment and follow-up strategies are necessary for those patients. NET tumor grade higher than G2, size larger than 1 cm, or located in the colon should be managed with radical surgery.
目的:本研究比较了结直肠神经内分泌肿瘤(cNEN)和结直肠腺癌伴神经内分泌分化(cNED)的生存率和转移发生率,并进一步探讨了其预后因素和治疗指标:方法:选取2009年1月至2020年12月在华西医院确诊为cNEN和cNED的患者为研究对象。计算诊断率和转移率。对cNEN手术患者的无进展生存期(PFS)进行单变量和多变量Cox分析,对转移性疾病采用广义线性回归分析:该研究共纳入435例患者,包括257例神经内分泌肿瘤(NET)、52例神经内分泌癌(NEC)、29例神经内分泌-非神经内分泌混合瘤(MiNEN)和97例NED患者,其中202例接受了局部切除术,233例接受了根治性切除术。与其他组别相比,MiNEN 组和 NEC 组的转移率更高(NED:28.9%,MiNEN:58.6%,NEC:65.4%,NET:8.6%,P 2(P = 0.040)分别与疾病进展有关。转移性 NET 的独立风险因素包括肿瘤分级 G2/G3(p 结论:cNEN 显示出很高的转移能力,诊断具有挑战性。有必要对这些患者采取更积极的治疗和随访策略。肿瘤分级高于 G2、体积大于 1 厘米或位于结肠的 NET 患者应接受根治性手术治疗。
{"title":"Treatment indicators and prognostic factors in colorectal neuroendocrine neoplasms and adenocarcinoma with neuroendocrine differentiation: a single center retrospective study.","authors":"Xiaoying Fu, Cun Wang, Yongyang Yu, Hai-Ning Chen","doi":"10.1007/s00384-024-04731-7","DOIUrl":"10.1007/s00384-024-04731-7","url":null,"abstract":"<p><strong>Purpose: </strong>This study compared survival and metastasis occurrence between colorectal neuroendocrine neoplasms (cNEN) and colorectal adenocarcinoma with neuroendocrine differentiation (cNED) and further explored their prognostic factors and treatment indicators.</p><p><strong>Methods: </strong>Patients diagnosed as cNEN and cNED in West China Hospital from January 2009 to December 2020 were enrolled. The diagnosis and metastasis rates were calculated. Univariate and multivariate Cox analyses were conducted for progression-free survival (PFS) in cNEN surgical patients, and generalized linear regression was used for metastatic disease.</p><p><strong>Result: </strong>The study enrolled 435 patients, including 257 neuroendocrine tumors (NET), 52 neuroendocrine carcinomas (NEC), 29 mixed neuroendocrine-non-neuroendocrine neoplasms (MiNEN), and 97 NED patients, of whom 202 received local resection, and 233 received radical resection. Metastasis rates were higher in MiNEN and NEC groups compared to other groups (NED: 28.9%, MiNEN: 58.6%, NEC: 65.4%, NET: 8.6%, p < 0.001). The liver is the main metastatic site in cNEN, whereas cNED metastasized to various sites. For NEC and MiNEN patients, colon location (p = 0.002) and T stage > 2 (p = 0.040) were associated with disease progression separately. Independent risk factors for metastatic NET included tumor grade G2/G3 (p < 0.001), colon location (p = 0.001), size ≥ 1 cm (p = 0.005), and CK20 partial positive (p < 0.001).</p><p><strong>Conclusion: </strong>cNEN show high metastatic capacity and are challenging to diagnose. More aggressive treatment and follow-up strategies are necessary for those patients. NET tumor grade higher than G2, size larger than 1 cm, or located in the colon should be managed with radical surgery.</p>","PeriodicalId":13789,"journal":{"name":"International Journal of Colorectal Disease","volume":"39 1","pages":"170"},"PeriodicalIF":2.5,"publicationDate":"2024-10-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11496372/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142464582","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-10-21DOI: 10.1007/s00384-024-04738-0
Mehran Ebrahimi Shah-Abadi, Haleh Pak, Alireza Kazemeini, Dorsa Najari, Seyed Mohsen Ahmadi Tafti, Mohammad Reza Keramati, Amir Keshvari, Mohammad Sadegh Fazeli, Behnam Behboudi
Introduction: Postoperative urinary dysfunction poses a significant challenge for rectal cancer patients. While pelvic floor muscle training (PFMT) has shown promise in other contexts, its efficacy following rectal cancer surgery remains uncertain.
Results: A clinical trial involving 79 rectal cancer patients found that initiating Kegel exercises post-surgery led to significant improvements in urinary symptoms compared to standard care. Adherence to exercises correlated with symptom reduction, with no reported adverse events. We have defined the main outcome of our study as the improvement in urinary function scores post-surgery. Effectiveness is considered as any statistically significant improvement in these scores.
Conclusion: Early initiation of Kegel exercises shows promise in alleviating postoperative urinary dysfunction in rectal cancer patients. Further research is needed to optimize postoperative care protocols and enhance patient outcomes.
{"title":"Effect of kegel pelvic floor muscle exercise on improving urinary disorder in rectum cancer patients after rectal surgery: a randomized clinical trial.","authors":"Mehran Ebrahimi Shah-Abadi, Haleh Pak, Alireza Kazemeini, Dorsa Najari, Seyed Mohsen Ahmadi Tafti, Mohammad Reza Keramati, Amir Keshvari, Mohammad Sadegh Fazeli, Behnam Behboudi","doi":"10.1007/s00384-024-04738-0","DOIUrl":"10.1007/s00384-024-04738-0","url":null,"abstract":"<p><strong>Introduction: </strong>Postoperative urinary dysfunction poses a significant challenge for rectal cancer patients. While pelvic floor muscle training (PFMT) has shown promise in other contexts, its efficacy following rectal cancer surgery remains uncertain.</p><p><strong>Results: </strong>A clinical trial involving 79 rectal cancer patients found that initiating Kegel exercises post-surgery led to significant improvements in urinary symptoms compared to standard care. Adherence to exercises correlated with symptom reduction, with no reported adverse events. We have defined the main outcome of our study as the improvement in urinary function scores post-surgery. Effectiveness is considered as any statistically significant improvement in these scores.</p><p><strong>Conclusion: </strong>Early initiation of Kegel exercises shows promise in alleviating postoperative urinary dysfunction in rectal cancer patients. Further research is needed to optimize postoperative care protocols and enhance patient outcomes.</p>","PeriodicalId":13789,"journal":{"name":"International Journal of Colorectal Disease","volume":"39 1","pages":"169"},"PeriodicalIF":2.5,"publicationDate":"2024-10-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11493781/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142464563","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Objective: Cytoreductive surgery (CRS) combined with hyperthermic intraperitoneal chemotherapy (HIPEC) is one of the most effective treatments for intraperitoneal malignancies. However, current research on risk factors for postoperative complications needs to be more consistent. This study aimed to conduct a meta-analysis of the risk factors for postoperative complications in CRS + HIPEC patients.
Methods: Studies meeting the inclusion criteria were screened by searching the Embase, PubMed, Cochrane and Web of Science databases. RevMan and STATA software were used to analyze the data extracted from the included articles.
Results: A total of 15 articles with 4021 patients were included in the meta-analysis. The results revealed that sex, elevated peritoneal cancer index, prolonged duration of surgery and smoking habits were risk factors for postoperative complications in CRS + HIPEC patients. In contrast, BMI, eGFR, age, history of preoperative chemotherapy, history of preoperative surgery, and history of neoadjuvant therapy had no significant effect on postoperative complications in the CRS + HIPEC group. The effects of diabetes, hypertension, preoperative albumin level, tumor location and chemotherapy regimen on the occurrence of complications need to be further investigated.
Conclusions: We identified several risk factors for postoperative complications after CRS + HIPEC, which should help clinicians minimize the incidence of postoperative complications and make more beneficial decisions for cancer patients who need treatment.
目的:腹腔镜手术(CRS)联合腹腔内热化疗(HIPEC)是治疗腹腔内恶性肿瘤最有效的方法之一。然而,目前对术后并发症风险因素的研究需要更加一致。本研究旨在对CRS + HIPEC患者术后并发症的风险因素进行荟萃分析:通过检索 Embase、PubMed、Cochrane 和 Web of Science 数据库筛选符合纳入标准的研究。使用RevMan和STATA软件分析从纳入文章中提取的数据:结果:共有 15 篇文章、4021 名患者被纳入荟萃分析。结果显示,性别、腹膜癌指数升高、手术时间过长和吸烟习惯是 CRS + HIPEC 患者术后并发症的危险因素。相比之下,BMI、eGFR、年龄、术前化疗史、术前手术史、新辅助治疗史对CRS + HIPEC组术后并发症无明显影响。糖尿病、高血压、术前白蛋白水平、肿瘤位置和化疗方案对并发症发生的影响有待进一步研究:我们发现了CRS + HIPEC术后并发症的几个风险因素,这应有助于临床医生最大限度地降低术后并发症的发生率,并为需要治疗的癌症患者做出更有利的决定。
{"title":"Risk factors for postoperative complications in patients undergoing cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy: A meta-analysis and systematic review.","authors":"Dengzhuo Chen, Yongli Ma, Jinghui Li, Liang Wen, Guosheng Zhang, Chengzhi Huang, Xueqing Yao","doi":"10.1007/s00384-024-04741-5","DOIUrl":"10.1007/s00384-024-04741-5","url":null,"abstract":"<p><strong>Objective: </strong>Cytoreductive surgery (CRS) combined with hyperthermic intraperitoneal chemotherapy (HIPEC) is one of the most effective treatments for intraperitoneal malignancies. However, current research on risk factors for postoperative complications needs to be more consistent. This study aimed to conduct a meta-analysis of the risk factors for postoperative complications in CRS + HIPEC patients.</p><p><strong>Methods: </strong>Studies meeting the inclusion criteria were screened by searching the Embase, PubMed, Cochrane and Web of Science databases. RevMan and STATA software were used to analyze the data extracted from the included articles.</p><p><strong>Results: </strong>A total of 15 articles with 4021 patients were included in the meta-analysis. The results revealed that sex, elevated peritoneal cancer index, prolonged duration of surgery and smoking habits were risk factors for postoperative complications in CRS + HIPEC patients. In contrast, BMI, eGFR, age, history of preoperative chemotherapy, history of preoperative surgery, and history of neoadjuvant therapy had no significant effect on postoperative complications in the CRS + HIPEC group. The effects of diabetes, hypertension, preoperative albumin level, tumor location and chemotherapy regimen on the occurrence of complications need to be further investigated.</p><p><strong>Conclusions: </strong>We identified several risk factors for postoperative complications after CRS + HIPEC, which should help clinicians minimize the incidence of postoperative complications and make more beneficial decisions for cancer patients who need treatment.</p>","PeriodicalId":13789,"journal":{"name":"International Journal of Colorectal Disease","volume":"39 1","pages":"167"},"PeriodicalIF":2.5,"publicationDate":"2024-10-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11489289/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142464580","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}